Skip Navigation


European Heart Journal Advance Access originally published online on May 25, 2008
European Heart Journal 2008 29(12):1481-1482; doi:10.1093/eurheartj/ehn229
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/12/1481    most recent
ehn229v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by George, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by George, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Erythropoietin and outcome prediction in patients with heart failure: the plot thickens...

Jacob George*

Cardiovascular Research Center and Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

* Corresponding author. Tel: +972 3 6974762, Fax: +972 3 546 9832, Email: jacobg@post.tau.ac.il

This editorial refers to ‘Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients’{dagger} by P. van der Meer et al., on page 1510

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

{dagger} doi:10.1093/eurheartj/ehn205 Back

The first 10% of the full text of this article appears below.

Heart failure syndromes represent a principal cause of morbidity and mortality in the Western world.1 The importance of measures for diagnosis, surveillance, and treatment of patients with chronic heart failure (CHF) are likely to attract increasing attention as the prevalence of the syndrome will rise with the ageing of the population. One of the most studied clinical determinants of outcome in patients with CHF is haemoglobin level.2 There are many reports showing that anaemia . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients
Peter van der Meer, Dirk J. Lok, James L. Januzzi, Pieta W. Bruggink-Andre de la Porte, Erik Lipsic, Jan van Wijngaarden, Adriaan A. Voors, Wiek H. van Gilst, and Dirk J. van Veldhuisen
EHJ 2008 29: 1510-1515. [Abstract] [FREE Full Text]  

Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients
Peter van der Meer, Dirk J. Lok, James L. Januzzi, Pieta W. Bruggink-Andre de la Porte, Erik Lipsic, Jan van Wijngaarden, Adriaan A. Voors, Wiek H. van Gilst, and Dirk J. van Veldhuisen
EHJ 2008 29: 1510-1515. [Abstract] [FREE Full Text]